KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Intramuscular Generic Injection (QLG2072) versus Haloperidol in Chinese Patients with Acute Agitation: A Phase 3 Multicenter, Randomized, Double-Blind, Active-Controlled Trial.

Fang Dong, Zhonggang Wang, Chao Li, Xuan Li, Daomin Zhu, Jie Li, Zhoubing Wang, Jian Gong, Jianchu Zhou, Huanzhong Liu, Yunshu Zhang, Xuehua Zhang, Xiuzhe Chen, Mei Yu, Xi Tan, Mincai Qian, Yu Luo, Wan-Jun Guo, Shiping Xie, Jinsong Huang, Jingyuan Zhao, Jianguo Wan, Yihui Shan, Nannan Li, Jie Wang, Yunfei Ju, Juan Wang, Qingtao Bian, Gang Wang

Drug Des Devel Ther 20 561494

PMID41778148
PMCIDPMC12951296
DOI10.2147/DDDT.S561494
发表日期2026-03-04
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1:非 KM 图;Figure 2:AI 判定为 other;Figure 3:森林图/亚组分析图。
摘要

摘要

INTRODUCTION: This multicenter, randomized, double-blind, phase 3 trial aimed to assess the efficacy and safety of generic olanzapine injection (QLG2072) in managing acute agitation associated with schizophrenia/bipolar I disorder in Chinese patients. METHODS: Patients with acute agitation associated with schizophrenia/bipolar I disorder were randomly (1:1) assigned to receive 1-3 intramuscular (IM) injections within a 24-hour treatment period, with either QLG2072 (10 mg per injection) or haloperidol (7.5 mg per injection). The primary endpoint was the change in Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) score from baseline to 2 hours post-injection, assessed against a pre-specified non-inferiority margin of 2.0 for QLG2072 versus haloperidol. RESULTS: A total of 318 participants were randomized; 159 and 158 were included in the olanzapine and haloperidol FAS groups, respectively. At 2 h post-injection, the adjusted mean reductions in PANSS-EC scores were -9.37 (95% confidence interval [CI]: -10.02 to -8.72) for QLG2072 versus -9.40 (95% CI: -10.04 to -8.75) for IM haloperidol with a between-group difference of 0.03 (95% CI: -0.88 to 0.93), establishing non-inferiority of QLG2072 to IM haloperidol, as the upper limit of the 95% CI fell below the predefined margin. Consistent with the primary endpoint, comparable efficacy was observed across multiple secondary efficacy measures, including response rate and the Clinical Global Impression-Improvement scores. The overall incidence of treatment-emergent adverse events was comparable between the treatment groups. However, QLG2072 was associated with a numerically lower incidence of extrapyramidal symptoms compared to haloperidol (10.1% vs 27.2%). DISCUSSION: QLG2072 demonstrated non-inferiority to haloperidol in acute agitation management, with comparable efficacy and favorable neurological tolerability. These findings support its clinical application in Chinese psychiatric populations. TRIAL REGISTRATION: ClinicalTrials.gov: NCT05803642.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Patient disposition.
非 KM Figure
Figure 2Mean changes in the Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) scores from baseline to each time point within 2 hours after the first intramuscular (IM) injection. * Indicates the differences of adjusted change between groups (IM olanzapine vs IM haloperidol), mean (95% CI) from 30 min to 120 min. Squares in boxes indicate the adjusted mean; the top box lines, upper quartile; the bottom box line, lower quartile; bars in boxes, median; whiskers, data falling within 1.5 times the interquartile range; dots, values outside the range indicated by the whiskers. The adjusted mean are the least squares estimated values after the pooled analysis of the covariance analysis model using the Rubin method. The covariance analysis model takes the change value of the PANSS-EC score at 2 h from baseline as the dependent variable, the treatment groups and stratification factors (schizophrenia vs bipolar I disorder) as fixed effects, and the baseline PANSS-EC score as the covariate. Missing PANSS-EC scores were imputed using the Markov Chain Monte Carlo (MCMC) multiple imputation method, under the assumption that missing data adhered to the missing-at-random mechanism.
非 KM Figure
Figure 3Forest plots of the change of PANSS-EC at 2 hours post the first intramuscular injection from baseline in the full analysis set. * The adjusted mean are the least squares estimated values after the pooled analysis of the covariance analysis model using the Rubin method.
非 KM Figure